About this program

This program aims at developing an anti-CD39 antibody for immuno-oncology. By targeting the adenosine immunosuppressive pathway, it has the potential to promote anti-tumor immune responses across a wide range of tumors.

CD39 is a membrane-bound extracellular enzyme overexpressed on both regulatory T cells and several cancer types. It plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression and dysregulation of immune cell infiltrates resulting in tumor spreading. Blockade of CD39 may therefore stimulate anti-tumor immunity across a wide range of tumors (including kidney, lung, ovarian, pancreatic, thyroid, testicular, endometrial, and prostate tumors, as well as in lymphoma and melanoma) by preventing the production of immunosuppressive adenosine and by promoting the accumulation of ATP in the tumor microenvironment.

IPH52 is a CD39-blocking antibody aiming at restoring a pro-inflammatory microenvironment. This program is currently in preclinical development at Innate Pharma.

Mechanism of action of anti-CD39